Docetaxel plus cisplatin: An active combination regimen in non-small- cell lung cancer

Richard J. Gralla, J. T. Cole, C. N. Robertson, C. B. Marques, C. N. Rittenberg

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Docetaxel (Taxotere) is a semisynthetic taxoid that possesses significant activity as a single agent in the treatment of patients with non- small cell lung cancer. In patients with advanced non-small-cell lung cancer who had previously failed cisplatin (Platinol)-based chemotherapy, 100 mg/m2 of docetaxel administered as an intravenous infusion over 1 hour, once every 3 weeks, produced a median response rate of 17% (of the intent-to-treat population) and median survival of 9 months. The present report describes the preliminary results from 3 phase II trials performed in the United States, France, and Australia, examining the combination of docetaxel and cisplatin in patients with advanced non-small-cell lung cancer. One trial (Australian) studied docetaxel administered as a 1-hour intravenous infusion followed by a 30-minute infusion of cisplatin on days 1, 22, and then every 3 weeks. The French and US trials administered docetaxel every 3 weeks, but gave cisplatin on days 1, 22, and then every 6 weeks. Major response rates ranged from 30% to 51% and median estimated survival ranged from 9 to 10.5 months. Based on the results of these trials, the recommended dose for future phase II and III trials in patients with advanced non-small-cell lung cancer is either 75 mg/m2 of docetaxel and 75 mg/m2 of cisplatin, or 65 mg/m2 of docetaxel and 100 mg/m2 of cisplatin, with docetaxel being administered once every 3 weeks and cisplatin on days 1, 22, and then every 6 weeks.

Original languageEnglish (US)
Pages (from-to)27-30
Number of pages4
JournalOncology
Volume11
Issue number7 SUPPL.
StatePublished - 1997
Externally publishedYes

Fingerprint

docetaxel
Non-Small Cell Lung Carcinoma
Cisplatin
Intravenous Infusions
Taxoids
Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Gralla, R. J., Cole, J. T., Robertson, C. N., Marques, C. B., & Rittenberg, C. N. (1997). Docetaxel plus cisplatin: An active combination regimen in non-small- cell lung cancer. Oncology, 11(7 SUPPL.), 27-30.

Docetaxel plus cisplatin : An active combination regimen in non-small- cell lung cancer. / Gralla, Richard J.; Cole, J. T.; Robertson, C. N.; Marques, C. B.; Rittenberg, C. N.

In: Oncology, Vol. 11, No. 7 SUPPL., 1997, p. 27-30.

Research output: Contribution to journalArticle

Gralla, RJ, Cole, JT, Robertson, CN, Marques, CB & Rittenberg, CN 1997, 'Docetaxel plus cisplatin: An active combination regimen in non-small- cell lung cancer', Oncology, vol. 11, no. 7 SUPPL., pp. 27-30.
Gralla RJ, Cole JT, Robertson CN, Marques CB, Rittenberg CN. Docetaxel plus cisplatin: An active combination regimen in non-small- cell lung cancer. Oncology. 1997;11(7 SUPPL.):27-30.
Gralla, Richard J. ; Cole, J. T. ; Robertson, C. N. ; Marques, C. B. ; Rittenberg, C. N. / Docetaxel plus cisplatin : An active combination regimen in non-small- cell lung cancer. In: Oncology. 1997 ; Vol. 11, No. 7 SUPPL. pp. 27-30.
@article{c4e8415b2a44442faf4213c305307580,
title = "Docetaxel plus cisplatin: An active combination regimen in non-small- cell lung cancer",
abstract = "Docetaxel (Taxotere) is a semisynthetic taxoid that possesses significant activity as a single agent in the treatment of patients with non- small cell lung cancer. In patients with advanced non-small-cell lung cancer who had previously failed cisplatin (Platinol)-based chemotherapy, 100 mg/m2 of docetaxel administered as an intravenous infusion over 1 hour, once every 3 weeks, produced a median response rate of 17{\%} (of the intent-to-treat population) and median survival of 9 months. The present report describes the preliminary results from 3 phase II trials performed in the United States, France, and Australia, examining the combination of docetaxel and cisplatin in patients with advanced non-small-cell lung cancer. One trial (Australian) studied docetaxel administered as a 1-hour intravenous infusion followed by a 30-minute infusion of cisplatin on days 1, 22, and then every 3 weeks. The French and US trials administered docetaxel every 3 weeks, but gave cisplatin on days 1, 22, and then every 6 weeks. Major response rates ranged from 30{\%} to 51{\%} and median estimated survival ranged from 9 to 10.5 months. Based on the results of these trials, the recommended dose for future phase II and III trials in patients with advanced non-small-cell lung cancer is either 75 mg/m2 of docetaxel and 75 mg/m2 of cisplatin, or 65 mg/m2 of docetaxel and 100 mg/m2 of cisplatin, with docetaxel being administered once every 3 weeks and cisplatin on days 1, 22, and then every 6 weeks.",
author = "Gralla, {Richard J.} and Cole, {J. T.} and Robertson, {C. N.} and Marques, {C. B.} and Rittenberg, {C. N.}",
year = "1997",
language = "English (US)",
volume = "11",
pages = "27--30",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "7 SUPPL.",

}

TY - JOUR

T1 - Docetaxel plus cisplatin

T2 - An active combination regimen in non-small- cell lung cancer

AU - Gralla, Richard J.

AU - Cole, J. T.

AU - Robertson, C. N.

AU - Marques, C. B.

AU - Rittenberg, C. N.

PY - 1997

Y1 - 1997

N2 - Docetaxel (Taxotere) is a semisynthetic taxoid that possesses significant activity as a single agent in the treatment of patients with non- small cell lung cancer. In patients with advanced non-small-cell lung cancer who had previously failed cisplatin (Platinol)-based chemotherapy, 100 mg/m2 of docetaxel administered as an intravenous infusion over 1 hour, once every 3 weeks, produced a median response rate of 17% (of the intent-to-treat population) and median survival of 9 months. The present report describes the preliminary results from 3 phase II trials performed in the United States, France, and Australia, examining the combination of docetaxel and cisplatin in patients with advanced non-small-cell lung cancer. One trial (Australian) studied docetaxel administered as a 1-hour intravenous infusion followed by a 30-minute infusion of cisplatin on days 1, 22, and then every 3 weeks. The French and US trials administered docetaxel every 3 weeks, but gave cisplatin on days 1, 22, and then every 6 weeks. Major response rates ranged from 30% to 51% and median estimated survival ranged from 9 to 10.5 months. Based on the results of these trials, the recommended dose for future phase II and III trials in patients with advanced non-small-cell lung cancer is either 75 mg/m2 of docetaxel and 75 mg/m2 of cisplatin, or 65 mg/m2 of docetaxel and 100 mg/m2 of cisplatin, with docetaxel being administered once every 3 weeks and cisplatin on days 1, 22, and then every 6 weeks.

AB - Docetaxel (Taxotere) is a semisynthetic taxoid that possesses significant activity as a single agent in the treatment of patients with non- small cell lung cancer. In patients with advanced non-small-cell lung cancer who had previously failed cisplatin (Platinol)-based chemotherapy, 100 mg/m2 of docetaxel administered as an intravenous infusion over 1 hour, once every 3 weeks, produced a median response rate of 17% (of the intent-to-treat population) and median survival of 9 months. The present report describes the preliminary results from 3 phase II trials performed in the United States, France, and Australia, examining the combination of docetaxel and cisplatin in patients with advanced non-small-cell lung cancer. One trial (Australian) studied docetaxel administered as a 1-hour intravenous infusion followed by a 30-minute infusion of cisplatin on days 1, 22, and then every 3 weeks. The French and US trials administered docetaxel every 3 weeks, but gave cisplatin on days 1, 22, and then every 6 weeks. Major response rates ranged from 30% to 51% and median estimated survival ranged from 9 to 10.5 months. Based on the results of these trials, the recommended dose for future phase II and III trials in patients with advanced non-small-cell lung cancer is either 75 mg/m2 of docetaxel and 75 mg/m2 of cisplatin, or 65 mg/m2 of docetaxel and 100 mg/m2 of cisplatin, with docetaxel being administered once every 3 weeks and cisplatin on days 1, 22, and then every 6 weeks.

UR - http://www.scopus.com/inward/record.url?scp=0030816111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030816111&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030816111

VL - 11

SP - 27

EP - 30

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 7 SUPPL.

ER -